BUSINESS
Fed policy: How do investors take position after a hawkish pause?
The possibility of further rate hikes by the Fed and the progress of monsoon can add volatility to the stock market
BUSINESS
Ami Organics: Multiple growth levers coming to the fore
Dominant presence in a few of the pharma intermediates and the emerging op-portunities in chemical applications are key growth drivers
BUSINESS
Nocil: China +1 theme is gradually building up amidst recessionary headwinds
Weak pricing environment weighs on margins
BUSINESS
Sun Pharma: Stretched valuation a sticking point, what else to watch out for?
Elevated promotional/travel expenses and increased competitive intensity would weigh on margins
BUSINESS
Balaji Amines: Does it merit a look?
Key monitorable to watch would be sustenance of operating margins for the subsidiary - Balaji Specialty
BUSINESS
Divi’s Lab: Sequential improvement, but long way to go
An improvement in gross margins is on the cards over the next three to four quarters
BUSINESS
Zydus Lifesciences: Time to book profit, post strong rally over a year?
Management is aiming for a single-digit growth in the US market for FY24 on the back of launches from the Moraiya facility.
BUSINESS
Navin Fluorine: Innovator-led growth to continue in FY24 for this pricey stock
Except for one molecule, the company is not witnessing any pricing pressure for Specialty chemicals as it has increasingly limited exposure to generics.
BUSINESS
Cipla: US business momentum to moderate
A compression in margins is plausible in the near term as employee and other pre-Covid expenses are likely to escalate
BUSINESS
SRF: Chemicals continue to shine, but all priced in
The EBITDA margins are likely to moderate in FY24
BUSINESS
Dr Reddy’s: Time to book profit?
Domestic portfolio rejig, limited-competition products launches in the US, and a ramp-up in China launches are key to the company’s performance
BUSINESS
Aarti Industries: Is it time to look past inventory headwinds?
FY24 could be another year of consolidation for the industry, unless global growth picks up.
BUSINESS
Fed policy: Is the end in sight for the rate hike cycle?
This could be an appropriate time to start portfolio construction as Fed commentary suggests that some of the financial stability concerns are abating
BUSINESS
Apcotex: Gradual ramp-up of new facilities to drive earnings
Apcotex has a volume-led growth visibility in the near to medium term and margins are expected to pick up later.
BUSINESS
Laurus Labs: Is the worst priced in?
We expect FY24 to be the year of consolidation for top-line growth. Margins are expected to bottom out as operating leverage kicks in first for formulation capacity and later on for CDMO opportunity.
BUSINESS
Syngene: Zoetis opportunity unfolds
Q4 FY23 aided by better-than-expected traction for the 10-year manufacturing deal with Zoetis.
BUSINESS
Is Unichem deal a misstep for Ipca Labs?
The utilisation of the idle assets of Unichem will be key to the success of the deal
BUSINESS
Mankind Pharma IPO: A pricey proposition on branded domestic pharma market
As the company is foraying into newer areas of therapies, particularly chronic, there could be execution hiccups.
BUSINESS
Fermenta Biotech: Time to look beyond near-term cyclical challenges?
Real estate monetization is on works
BUSINESS
Oil Update: What should investors do after the OPEC shocker?
Portfolio construction should be focused on business models that can survive high cost of capital; avoid pockets where the margin of safety is limited
BUSINESS
Sun Pharma: Ransomware attack to eat into operational performance
The situation is evolving and can potentially have a wider reach, possibly involving litigations
BUSINESS
Fed policy: Banking crises may turn out to be a blessing in disguise for inflation goals
Uncertainty and risk to upside in inflation has reduced; the sooner financial stability is achieved is better for investors
BUSINESS
Can the Credit Suisse deal lend enough confidence to Fed in fighting inflation?
High inflation and high interest regime in the longer term would present more complex challenges, not just liquidity
BUSINESS
Ami Organics: Europe plus one trend is taking hold
For the specialty chemicals business, Ami Organics is expanding on the clientele side and investing in process engineering
